Quick answer: Depression affects 280 million people worldwide according to the WHO, yet the conventional model — monoamine deficiency corrected by antidepressants — explains fewer than 50% of cases and fails to account for the 30-40% of patients who don’t respond to first-line SSRI therapy. Functional psychiatry identifies the upstream biological drivers of mood disorders: neuroinflammation, HPA axis dysregulation, gut-brain axis disruption, nutritional deficiencies, hormonal imbalances, mitochondrial dysfunction, and genetic variants in neurotransmitter metabolism.
Why the Monoamine Hypothesis Is Incomplete
The serotonin deficiency theory of depression — dominant in medical education and pharmaceutical marketing since the 1990s — has faced increasing scientific challenge. Moncrieff et al. 2022 (Molecular Psychiatry, umbrella review) found no consistent evidence that depression is associated with lower serotonin activity or levels in the reviewed studies. This does not mean SSRIs don’t work — they demonstrably help many patients — but it suggests their mechanism of action may be more complex than simple serotonin correction, and that serotonin deficiency is not the singular cause of depression requiring correction.
More critically, the monoamine model offers no explanation for why antidepressants fail in 30-40% of patients (treatment-resistant depression, TRD), why depression so frequently co-occurs with physical illnesses (autoimmune conditions, metabolic syndrome, thyroid disorders, chronic infections), or why anti-inflammatory interventions produce antidepressant effects in specific populations.
Functional psychiatry doesn’t reject pharmacotherapy — it contextualizes it within a broader biological framework, identifying which patients will respond to which interventions and addressing the upstream drivers that antidepressants alone cannot correct.
The Neuroinflammation Model of Depression
The inflammatory model of depression is now one of the most robustly supported paradigms in psychiatry. Miller and Raison 2016 (Nature Reviews Immunology) established the evidence base: elevated inflammatory biomarkers (CRP, IL-6, TNF-α, IL-1β) are present in approximately 30-40% of depressed patients, and this inflammatory subtype shows reduced response to antidepressants but improved response to anti-inflammatory interventions.
The mechanism: inflammatory cytokines activate indoleamine 2,3-dioxygenase (IDO) — an enzyme that diverts tryptophan metabolism away from serotonin synthesis and toward the kynurenine pathway. The kynurenine pathway produces quinolinic acid — an NMDA receptor agonist and excitotoxin that contributes to hippocampal damage and the neuroplasticity deficit central to depression. Haroon et al. 2014 demonstrated elevated cerebrospinal fluid kynurenine metabolites in depressed patients with high peripheral inflammation.
The clinical implication: in patients with depressive symptoms plus elevated hsCRP (>1 mg/L), TNF-α, IL-6, or other inflammatory markers, addressing the inflammatory driver is at least as important as — and possibly more important than — serotonergic intervention. Raison et al. 2013 JAMA Psychiatry demonstrated infliximab (TNF-α blocker) produced significant antidepressant effects specifically in patients with high baseline CRP — not in those with normal CRP.
Functional medicine approach: identify the inflammatory source (gut dysbiosis, food sensitivities, autoimmunity, obesity-driven adipokines, chronic infections, sleep deprivation, psychosocial stress), reduce inflammatory burden, and monitor inflammatory markers alongside mood outcomes.
The Gut-Brain Axis: Bidirectional Depression Pathways
The enteric nervous system contains approximately 100 million neurons — more than the spinal cord — and communicates bidirectionally with the brain via the vagus nerve, immune signaling, and the microbiome-gut-brain axis. Approximately 90% of serotonin in the body is produced by enterochromaffin cells in the gut mucosa, where it regulates peristalsis and influences gut-brain signaling through vagal afferents.
The psychobiotic revolution: Dinan and Cryan 2013 coined “psychobiotics” — specific probiotic strains with demonstrable effects on brain function and mental health. The evidence has expanded substantially:
Lactobacillus rhamnosus JB-1 reduced anxiety and depression-related behaviors in mice and modulated GABA receptor expression in multiple brain regions in a vagus nerve-dependent manner (Bravo et al. 2011 PNAS). The effect was abolished by vagotomy — confirming the gut-vagus-brain signaling axis.
The Perna et al. 2019 meta-analysis (Oxidative Medicine and Cellular Longevity) of 34 RCTs found probiotic supplementation significantly reduced depression scores (SMD -0.40) and anxiety scores (SMD -0.36) vs placebo, with effects most pronounced in clinical (vs healthy) populations. Multi-strain formulations showed larger effects than single strains.
The Valles-Colomer et al. 2019 Nature Microbiology population study (n=1,054) identified Coprococcus and Dialister as gut bacteria consistently depleted in depressed individuals — and notably, their abundance correlated with quality of life independent of antidepressant use. These butyrate-producing species likely exert anti-inflammatory and neuroprotective effects via short-chain fatty acid production.
Gut repair for mental health: the same 5R protocol used for physical gut conditions applies to psychiatric functional medicine — remove dietary triggers, replace digestive enzymes, reinoculate with evidence-based psychobiotics, repair intestinal permeability, rebalance with prebiotic fiber. Psychological symptoms often improve in parallel with gut symptoms.
Nutritional Deficiencies and Mood: The Evidence
Multiple nutritional deficiencies have robust associations with depression and anxiety, yet psychiatric evaluations rarely include nutritional assessment:
Omega-3 fatty acids (EPA/DHA): The strongest nutritional evidence in psychiatry. Meta-analysis by Sublette et al. 2011 (Journal of Clinical Psychiatry, 15 RCTs) found EPA ≥60% of total omega-3 in the formulation produces significant antidepressant effects (effect size 0.53). Martins 2009 meta-analysis confirmed antidepressant efficacy of omega-3 specifically for EPA-dominant formulations. Mechanism: EPA reduces neuroinflammation, improves serotonin and dopamine neurotransmission, and incorporates into neuronal membrane phospholipids improving signal transduction. Clinical target: EPA 1-2g/day from EPA-dominant fish oil; DHA less effective as monotherapy.
Vitamin D: Serotonin synthesis is directly regulated by vitamin D — the serotonin gene (tryptophan hydroxylase 2) contains a vitamin D response element, and adequate vitamin D is required for its transcription (Patrick and Ames 2015 FASEB Journal). Meta-analysis by Shaffer et al. 2014 (British Journal of Psychiatry, 31,424 participants) found significant inverse association between serum 25-OHD and depression. Spedding 2014 meta-analysis of supplementation RCTs found significant antidepressant effects of vitamin D when correcting deficiency vs placebo. Functional medicine target: 25-OHD 50-80 ng/mL.
Magnesium: Required for NMDA receptor regulation, HPA axis modulation, and over 300 enzymatic reactions. Serum magnesium inversely correlates with depression in epidemiological studies (Jacka 2009 Australian and New Zealand Journal of Psychiatry n=4,787). Tarleton 2017 (PLoS ONE) open-label RCT: magnesium chloride 248mg/day produced significant improvement in PHQ-9 depression scores within 2 weeks in adults with mild-to-moderate depression, equivalent to antidepressant effect sizes in some benchmarks. Magnesium L-threonate crosses the blood-brain barrier more effectively than other forms (Slutsky 2010 Neuron demonstrated improved synaptic density and cognitive function in rodents).
B vitamins — the methylation-mood connection: Folate and B12 deficiency are the most established nutritional risk factors for depression. Papakostas 2004 meta-analysis found low folate in 30% of depressed patients. MTHFR C677T homozygosity — present in ~10% of the population — impairs conversion of folate to 5-methyltetrahydrofolate (5-MTHF), reducing SAM synthesis and methylation capacity. SAM is the methyl donor for all monoamine neurotransmitters — serotonin methylation to melatonin, norepinephrine methylation by COMT, and histamine clearance by HNMT. Papakostas 2012 JAMA Psychiatry demonstrated l-methylfolate (15mg/day) as adjunctive therapy significantly improved antidepressant response rates in SSRI-resistant patients — with genetic benefit concentrated in MTHFR TT homozygotes.
Zinc: Acts as an NMDA receptor modulator, inhibiting excessive glutamate neurotransmission (excitotoxicity). Serum zinc inversely correlates with depression severity across multiple studies (Cope and Levenson 2010). Swardfager 2013 meta-analysis (Biological Psychiatry): serum zinc significantly lower in depressed vs control subjects. Zinc supplementation RCTs show adjunctive benefit when added to antidepressants (Nowak et al. 2003 Polish Journal of Pharmacology). Zinc is particularly depleted by stress (cortisol reduces zinc absorption), alcohol, and poor diet.
Iron: Iron deficiency — even without frank anemia — impairs dopamine synthesis (dopamine β-hydroxylase requires iron) and serotonin synthesis (tryptophan hydroxylase requires iron as cofactor). Murray-Kolb and Beard 2007 (American Journal of Clinical Nutrition, RCT) demonstrated iron supplementation significantly improved mood, attention, and learning in iron-deficient non-anemic women. Ferritin below 30 ng/mL is the functional medicine threshold for iron adequacy assessment in psychiatric contexts — substantially lower than the conventional laboratory “normal” range lower limit of 12-15 ng/mL.
HPA Axis and Cortisol Dysregulation in Anxiety and Depression
The hypothalamic-pituitary-adrenal (HPA) axis is dysregulated in the majority of patients with major depression — with approximately two-thirds showing HPA hyperactivation (elevated cortisol, reduced cortisol suppression on dexamethasone test) and a minority showing HPA hypoactivation (hypocortisolism associated with PTSD, chronic fatigue, and burnout). These are mechanistically distinct subtypes requiring different interventions.
Elevated cortisol damages hippocampal neurons via glucocorticoid receptor-mediated apoptosis — explaining the hippocampal volume reduction (3-10% loss) documented on MRI in chronic depression (McEwen 2001 Annual Review of Neuroscience). BDNF (brain-derived neurotrophic factor) — the neuroplasticity signal that promotes hippocampal neurogenesis — is suppressed by chronic cortisol and is mechanistically central to the neuroplasticity hypothesis of depression (Duman and Monteggia 2006 Neuron).
The DUTCH (Dried Urine Test for Comprehensive Hormones) provides the most comprehensive HPA axis assessment available outside research settings — mapping cortisol at 5 timepoints across the day, free vs total cortisol metabolites, cortisol awakening response, and DHEA/DHEAS. This information allows precise characterization of HPA subtype to guide targeted intervention: phosphatidylserine for cortisol reduction (Hellhammer 2004), DHEA restoration for HPA-hypoactivation states, Rhodiola and ashwagandha as adaptogens, and cognitive-behavioral interventions targeting the stress-cortisol feedback loop.
Thyroid and Hormonal Drivers of Mood
Thyroid hormones profoundly regulate mood, cognition, and energy — yet the standard psychiatric evaluation rarely includes thyroid testing, and even when ordered, often only measures TSH without the full functional panel.
Hypothyroidism and depression: Thyroid hormone regulates serotonin receptor sensitivity, brain glucose metabolism, and mitochondrial energy production. Subclinical hypothyroidism (TSH 2.5-10 mIU/L with normal T4) is associated with depression, fatigue, cognitive impairment, and anxiety — yet often dismissed as “normal.” Bauer et al. 2003 (Psychoneuroendocrinology) demonstrated subclinical hypothyroidism in 30% of bipolar patients and 17% of unipolar depression patients vs 10% of controls. In treatment-resistant depression, thyroid hormone augmentation (T3/Cytomel) is an established strategy — the STAR*D trial showed T3 augmentation produced remission in 25% of SSRI-resistant patients (Nierenberg 2006 NEJM).
Hashimoto’s encephalopathy and mood: Anti-thyroid antibodies — particularly anti-TPO and anti-thyroglobulin — can produce neuropsychiatric symptoms (cognitive dysfunction, mood instability, psychosis) independent of thyroid function levels. Screening TPO/anti-Tg antibodies in patients with unexplained psychiatric symptoms, particularly with positive family history of thyroid disease, is essential functional medicine practice.
Sex hormones and mood: Estrogen upregulates serotonin receptor expression and serotonin transporter (SERT) activity — explaining the post-partum, perimenstrual, and perimenopausal periods of increased mood vulnerability. Progesterone’s metabolite allopregnanolone is a potent positive allosteric modulator of GABA-A receptors — the same mechanism as benzodiazepines. PMDD (premenstrual dysphoric disorder) reflects GABA-A receptor sensitivity abnormality to normal luteal-phase progesterone fluctuations (Sundstrom-Poromaa 2017). Low testosterone in men — increasingly prevalent with obesity, aging, and environmental estrogen exposure — is independently associated with depression (Pope et al. 2003 JAMA demonstrated testosterone treatment antidepressant effects in hypogonadal men with treatment-resistant depression).
Genetic Variants in Neurotransmitter Metabolism
Pharmacogenomic and psychiatric genetics have identified several high-yield variants that guide functional psychiatry intervention:
MTHFR (C677T, A1298C): As described above — impairs methylation capacity and SAM synthesis, reducing neurotransmitter methylation. The most actionable variant in functional psychiatry: methylfolate supplementation produces measurable improvement in antidepressant response. Genetic testing identifies the 10-15% of the population with homozygous C677T who have the greatest methylation impairment.
COMT Val158Met: Catechol-O-methyltransferase degrades dopamine, norepinephrine, and catechol estrogens. Val/Val (fast COMT) — high enzyme activity, lower dopamine prefrontal cortex levels, reduced executive function but more resilient under stress. Met/Met (slow COMT) — low enzyme activity, higher dopamine levels, better executive function at baseline but “worrier” phenotype with amplified stress response and anxiety. COMT genotype predicts differential response to dopaminergic medications and cognitive training; it also influences estrogen metabolism and breast cancer risk.
SLC6A4 (5-HTTLPR serotonin transporter): The short/short genotype of the serotonin transporter gene was associated with increased depression risk under life stress in the landmark Caspi et al. 2003 Science study (n=847, prospective). The interaction between 5-HTTLPR genotype and stressful life events has been replicated in some meta-analyses but remains controversial. More practically, 5-HTTLPR genotype may predict SSRI response — though pharmacogenomic testing for this application is not yet standard of care.
CYP2D6 and CYP2C19: Phase I drug metabolism genes — critical for antidepressant dosing. CYP2D6 poor metabolizers (7-10% of Caucasians) cannot convert prodrugs like codeine and may have dramatically elevated SSRI/tricyclic levels at standard doses — producing toxicity. CYP2C19 rapid metabolizers may require higher escitalopram or citalopram doses for therapeutic effect. GeneSight and similar pharmacogenomic testing panels now provide this information clinically, meaningfully reducing psychiatric medication trial-and-error.
Mitochondrial Function and Mood: The Energy-Psychiatry Connection
The brain consumes 20% of total body oxygen despite representing only 2% of body weight — making it the organ most sensitive to mitochondrial dysfunction. Emerging evidence positions mitochondrial bioenergetics as central to mood disorder pathophysiology:
Gardner et al. 2003 (American Journal of Psychiatry) found significantly lower platelet mitochondrial Complex I activity in depressed patients vs controls. Nierenberg et al. 2013 systematic review documented mitochondrial dysfunction markers (elevated lactate/pyruvate ratio, reduced Complex I/IV activity, mtDNA deletions) in bipolar disorder. The ketogenic diet — which shifts brain fuel from glucose to ketone bodies, bypassing Complex I — has shown antidepressant and mood-stabilizing effects in emerging case series and small trials (Gilbert-Jaramillo 2019, El-Mallakh 2013), potentially via improved mitochondrial efficiency and reduced neuroinflammation.
Mitochondrial support in functional psychiatry: CoQ10 (200-400mg/day ubiquinol form), PQQ (pyrroloquinoline quinone — stimulates mitochondrial biogenesis), B vitamins (cofactors for all Krebs cycle enzymes), L-carnitine (mitochondrial fatty acid transport — Nasca 2018 PNAS demonstrated low carnitine in depressed patients and antidepressant-like effects of acetyl-L-carnitine in rodents), and exercise (the most potent non-pharmacological mitochondrial biogenesis stimulus).
The Functional Medicine Anxiety-Depression Evaluation
A complete functional psychiatry evaluation at The Private Practice assesses the biological terrain underlying mood and anxiety symptoms:
Laboratory assessment: CBC with differential (iron deficiency, inflammation); comprehensive metabolic panel; thyroid panel (TSH, fT3, fT4, anti-TPO, anti-Tg); 25-OHD vitamin D; magnesium RBC (more accurate than serum); zinc; B12/folate; homocysteine (methylation proxy); hsCRP (neuroinflammation marker); fasting insulin + glucose (metabolic-mood connection); full sex hormone panel (testosterone, estradiol, progesterone, DHEA-S, SHBG); DUTCH complete for HPA axis; omega-3 index (HS-Omega-3 Index target >8%); comprehensive stool analysis (gut-brain axis); IgG food sensitivity panel.
Genetic assessment: MTHFR genotyping (C677T, A1298C) — minimum recommended; broader methylation panel (COMT, CBS, MTRR) for complex cases; CYP2D6/CYP2C19 pharmacogenomics before medication prescribing.
Functional assessment: Validated questionnaires (PHQ-9, GAD-7, DASS-42); DUTCH complete; cognitive screening where indicated (MoCA); functional assessment of exercise capacity, sleep quality, and dietary patterns using validated tools.
The result is a precision psychiatry roadmap: identifying whether a patient’s depression is inflammatory (prioritize anti-inflammatory interventions), methylation-driven (prioritize methylfolate, B12), hormonal (prioritize thyroid/sex hormone optimization), nutritional (prioritize targeted repletion), or multi-factorial (address simultaneously with a staged protocol). Pharmacotherapy remains available and appropriate — but within a biological framework that maximizes response probability and minimizes trial-and-error.
If your mood disorder has not responded adequately to conventional treatment, or if you have multiple physical symptoms alongside psychiatric symptoms suggesting an underlying biological driver, functional psychiatry evaluation may reveal the root causes that antidepressants alone cannot address. To schedule a comprehensive functional psychiatry evaluation with Dr. Biernacki, call (810) 206-1402 or visit theprivatepractice.co.
Frequently Asked Questions About Functional Psychiatry
Q: Can neuroinflammation cause depression even without obvious physical illness?
A: Yes. Neuroinflammation can be driven by gut dysbiosis, food sensitivities (particularly gluten), sleep deprivation (even mild chronic sleep restriction elevates IL-6 and CRP), psychological stress (which activates NF-κB signaling and cytokine production), obesity (adipose tissue produces TNF-α and IL-6 constitutively), and subclinical infections — none of which produce obvious physical illness while creating significant neuroinflammatory burden. The Miller and Raison 2016 framework specifically identifies this “smoldering” neuroinflammation as distinct from the inflammation of obvious infectious or autoimmune disease.
Q: Does l-methylfolate work if I don’t have MTHFR variants?
A: Potentially. The Papakostas 2012 JAMA Psychiatry trial used l-methylfolate in SSRI-non-responders regardless of MTHFR genotype and found significant benefit — though the benefit was concentrated in those with genetic or biomarker evidence of methylation impairment (MTHFR TT genotype, elevated SAH, low folate). For patients without MTHFR variants but with elevated homocysteine, food folate inadequacy, or inflammatory depression subtype, l-methylfolate may still provide benefit via separate mechanisms including BDNF upregulation and tetrahydrobiopterin (BH4) recycling — a cofactor for all monoamine neurotransmitter syntheses.
Q: How is functional psychiatry different from integrative psychiatry?
A: Integrative psychiatry typically combines conventional psychiatric care with complementary modalities (mindfulness, acupuncture, nutraceuticals) as adjuncts. Functional psychiatry specifically applies functional medicine methodology — identifying and addressing root cause biological drivers using laboratory testing and personalized intervention protocols — rather than defaulting to symptom-based diagnosis and medication. Both approaches value the therapeutic relationship and mind-body medicine, but functional psychiatry has a more systematic laboratory-driven investigative framework.
Q: What is the evidence for exercise in treating depression and anxiety?
A: The evidence is remarkably strong. Blumenthal 1999 JAMA (n=156) found aerobic exercise equivalent to sertraline in reducing major depression scores at 16 weeks, with a significantly lower relapse rate at 10-month follow-up (8% vs 38%). The Schuch 2016 meta-analysis (Preventive Medicine, 25 RCTs) confirmed exercise significantly reduces depression (OR 0.52, 95% CI 0.34-0.79) as adjunct to antidepressant therapy. Mechanisms: exercise increases BDNF (Cotman 2002), suppresses inflammatory cytokines, improves HPA axis regulation, increases hippocampal neurogenesis (Erickson 2011 PNAS, hippocampal volume increase with aerobic exercise in older adults), normalizes circadian rhythms, and increases dopamine/norepinephrine release. A minimum of 150 minutes/week moderate aerobic exercise produces antidepressant effects — resistance training shows independent mood benefits (Gordon 2018 JAMA Psychiatry meta-analysis).